Top

Published in:

01-09-2004 | Letter to the Editors

Immunotherapy with histamine and interleukin 2 in malignant melanoma with liver metastasis

Authors: Sanjiv S. Agarwala, Kristoffer Hellstrand, Kurt Gehlsen, Peter Naredi

Published in: Cancer Immunology, Immunotherapy | Issue 9/2004

Excerpt

The long-term survival of patients with distant metastatic (stage IV) melanoma remains worryingly poor: approximately one fifth of patients are alive at 2 years after the occurrence of distant metastases, and the reduction of tumor burden achieved by chemotherapeutic regimens has not yet translated into a significant survival prolongation. The prognosis for those diagnosed with metastases in visceral organs, with the liver as the dominant site, is particularly dismal with a median survival time of 2–5 months, and <10% of patients surviving at 2 years [1]. …

Manola J, Atkins M, Ibrahim J, Kirkwood J (2000) Prognostic factors in metastatic melanoma: a pooled analysis of eastern cooperative oncology group trials. J Clin Oncol 18:3782

Atkins MB (2002) Interleukin-2: clinical applications. Semin Oncol 3:S7–S12

Kono K, Salazar-Onfray F, Petersson M, Hansson J, Masucci G, Wasserman K, Nakazawa T, Anderson P, Kiessling R (1996) Hydrogen peroxide secreted by tumour-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumour-specific T cell- and natural killer cell-mediated cytotoxicity. Eur J Immunol 26:1308

Zea AH, Curti BD, Longo DL, Alvord WG, Strobl SL, Mizoguchi H, Creekmore SP, O‘Shea JJ, Powers GC, Urba WJ (1995) Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin Cancer Res 1:1327

Kiessling R, Wasserman K, Horiguchi S, Kono K, Sjoberg J, Pisa P, Petersson M (1999) Tumor-induced immune dysfunction. Cancer Immunol Immunother 48:353

Hellstrand K, Asea A, Hermodsson S (1994) Histaminergic regulation of natural killer cell function: role of monocyte-derived reactive oxygen metabolites. J Immunol 153:4940

Hellstrand K, Asea A, Hermodsson S (1990) Role of histamine in natural killer cell mediated resistance against tumor cells. J Immunol 145:4365

Hellstrand K, Naredi P, Lindner P, Lundholm K, Hermodsson S, Rudenstam CM, Azstély M, Hafström LO (1994) Histamine in immunotherapy of advanced melanoma. Cancer Immunol Immunother 39:416

Agarwala SS, Glaspy J, O’Day SJ, Mitchell M, Gutheil J, Whitman E, Gonzalez R, Hersh E, Feun L, Belt R, Meyskens F, Hellstrand K, Wood D, Kirkwood JM, Gehlsen KR, Naredi, P (2002) Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol 20:125

10.

Hellstrand K (2002) Histamine in cancer immunotherapy: a preclinical background. Semin Oncol 29[Suppl 7]:35

11.

Saba TM (1970) Physiology and patophysiology of the reticuloendothelial system. Arch Intern Med 126:1031

Title: Immunotherapy with histamine and interleukin 2 in malignant melanoma with liver metastasis
Authors: Sanjiv S. Agarwala
Kristoffer Hellstrand
Kurt Gehlsen
Peter Naredi
Publication date: 01-09-2004
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 9/2004
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-004-0537-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 9/2004

Monitoring the level of complement components during autologous blood stem cell transplantation in patients with malignant lymphomas

Activated vitronectin as a target for anticancer therapy with human antibodies

Dendritic cells can be rapidly expanded ex vivo and safely administered in patients with metastatic breast cancer

Correlation between interleukin 6 production and tumor proliferation in non-small cell lung cancer

Immunotherapy in multiple myeloma: Id-specific strategies suggested by studies in animal models

Efficient generation of antileukemic autologous T cells by short-term culture and γ-irradiation of myeloid leukemic cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer